Company news

Johnson & Johnson news in 2026

Johnson & Johnson's news releases, calls and decks from 2026, newest first.

View company

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

February 17, 2026

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens[1] for Astigmatic Adults living with Presbyopia

February 9, 2026

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

February 6, 2026

Johnson & Johnson Named Inaugural Global Impact Award Winner by the Healthcare Businesswomen's Association (HBA)

February 5, 2026

Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months

February 2, 2026

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

January 27, 2026

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

January 27, 2026

Resolve M Therapeutics exits from stealth

January 22, 2026

Johnson & Johnson reports Q4 and Full-Year 2025 results

January 21, 2026

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

January 14, 2026

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

January 13, 2026

Distalmotion Secures Strategic Investment to Advance ASC Expansion of the DEXTER® Robotic Surgery System

January 12, 2026

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

January 10, 2026

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

January 8, 2026

Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

January 7, 2026

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma

January 6, 2026

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

January 2, 2026

← Newer news releases

Calls in 2026

Decks in 2026